Novel treatment options for secondary hyperparathyroidism in end-stage kidney disease patients on hemodialysis therapy

Остеопороз и остеопатии

Zhanna E. Belaya¹  Alexander S. Lutsenko¹  Liudmila Y. Rozhinskaya¹ 

[1] Endocrinology Research Centre;

关键词: secondary hyperparathyroidism;    chronic kidney failure;    hemodialysis;    calcimimetic agents;   

DOI  :  10.14341/osteo2017126-33

来源: DOAJ

【 摘 要 】

Pathogenesis of secondary hyperparathyroidism is based on D-hormone deprivation, leading to bone remodeling impairment, increase in FGF-23, PTH levels, changes in blood calcium and phosphorus levels. Taken together with alteration of calcium-sensing receptor (CaSR) sensitivity, these changes result in alteration of bone structure and cardiovascular complications. CaSR agonists are one of the most important medications for treatment of secondary hyperparathyroidism in dialysis patients. Until recently, there was only one CaSR agonist with proven effectivenesscinacalcet, which is administered per os, daily. Now, a new drug is registered in US, Europe and Russiaetelcalcetide, which is administered intravenously 3 times a week. In this review we focus on results of clinical trials regarding etelcalcetide effectiveness and possible compliance benefits.

【 授权许可】

Unknown